GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (FRA:SCP) » Definitions » Shares Outstanding (EOP)

Scancell Holdings (FRA:SCP) Shares Outstanding (EOP) : 819.98 Mil (As of Oct. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Scancell Holdings Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Scancell Holdings's shares outstanding for the quarter that ended in Oct. 2023 was 819.98 Mil.

Scancell Holdings's quarterly shares outstanding increased from Apr. 2023 (819.22 Mil) to Oct. 2023 (819.98 Mil). It means Scancell Holdings issued new shares from Apr. 2023 to Oct. 2023 .

Scancell Holdings's annual shares outstanding increased from Apr. 2022 (815.54 Mil) to Apr. 2023 (819.22 Mil). It means Scancell Holdings issued new shares from Apr. 2022 to Apr. 2023 .


Scancell Holdings Shares Outstanding (EOP) Historical Data

The historical data trend for Scancell Holdings's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scancell Holdings Shares Outstanding (EOP) Chart

Scancell Holdings Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 396.27 495.96 815.54 815.54 819.22

Scancell Holdings Semi-Annual Data
Apr14 Oct14 Apr15 Oct15 Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 815.54 815.54 818.72 819.22 819.98

Competitive Comparison of Scancell Holdings's Shares Outstanding (EOP)

For the Biotechnology subindustry, Scancell Holdings's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scancell Holdings's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scancell Holdings's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Scancell Holdings's Shares Outstanding (EOP) falls into.



Scancell Holdings Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Scancell Holdings  (FRA:SCP) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Scancell Holdings Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Scancell Holdings's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Scancell Holdings (FRA:SCP) Business Description

Traded in Other Exchanges
Address
Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings (FRA:SCP) Headlines

No Headlines